A novel SCN5A mutation associated with drug induced Brugada type ECG by Isik, Turker et al.
TitleA novel SCN5A mutation associated with drug inducedBrugada type ECG
Author(s)
Isik, Turker; Takeru, Makiyama; Matteo, Vatta; Hideki, Itoh;
Takeshi, Ueyama; Akihiko, Shimizu; Tomohiko, Ai; Minoru,
Horie




© 2016 Turker et al. This is an open access article distributed
under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction






A Novel SCN5AMutation Associated with
Drug Induced Brugada Type ECG
Isik Turker1¤, Takeru Makiyama2, Matteo Vatta3, Hideki Itoh4, Takeshi Ueyama5,
Akihiko Shimizu5, Tomohiko Ai1,6☯*, Minoru Horie4☯*
1 Krannert Institute of Cardiology, Indiana University, Indianapolis, IN, United States of America,
2 Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3 Department of
Cardiovascular Genetics, Indiana University, Indianapolis, IN, United States of America, 4 Cardiovascular
and Respiratory Medicine, Shiga Univ. School of Medicine, Otsu, Japan, 5 Cardiology, Yamaguchi
University School of Medicine, Yamaguchi, Japan, 6 Molecular Pathogenesis, Medical Research Institute,
Tokyo Medical and Dental University, Tokyo, Japan
☯ These authors contributed equally to this work.
¤ Current address: Navicent Health, Macon, GA, United States of America
* horie@belle.shiga-med.ac.jp (MH); ait@iu.edu (TA)
Abstract
Background
Class IC antiarrhythmic agents may induce acquired forms of Brugada Syndrome. We have
identified a novel mutation in SCN5A, the gene that encodes the α-subunit of the human
cardiac sodium channel (hNav1.5), in a patient who exhibited Brugada- type ECG changes
during pharmacotherapy of atrial arrhythmias.
Objective
To assess whether the novel mutation p.V1328M can cause drug induced Brugada Syndrome.
Methods
Administration of pilsicainide, a class IC antiarrhythmic agent, caused Brugada- type ST
elevation in a 66-year-old Japanese male who presented with paroxysmal atrial fibrillation
(PAF), type I atrial flutter and inducible ventricular fibrillation (VF) during electrophysiologi-
cal study. Genetic screening using direct sequencing identified a novel SCN5A variant, p.
V1328M. Electrophysiological parameters of WT and p.V1328M and their effects on drug
pharmacokinetics were studied using the patch-clamp method.
Results
Whole-cell sodium current densities were similar for WT and p.V1328M channels. While p.
V1328Mmutation did not affect the voltage-dependence of the activation kinetics, it caused
a positive shift of voltage-dependent steady-state inactivation by 7 mV. The tonic block in
the presence of pilsicainide was similar in WT and p.V1328M, when sodium currents were
induced by a low frequency pulse protocol (q15s). On the contrary, p.V1328Mmutation
enhanced pilsicainide induced use-dependent block at 2 Hz. (Ki: WT, 35.8 μM; V1328M,
19.3 μM).
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Conclusion
Our study suggests that a subclinical SCN5Amutation, p.V1328M, might predispose indi-
viduals harboring it to drug-induced Brugada Syndrome.
Introduction
Pilsicainide, a class IC antiarrhythmic agent, has been widely used in Japan for the diagnosis
and treatment of atrial arrhythmias [1, 2], as well as in the diagnosis of Brugada Syndrome [3,
4]. It is hypothesized that antiarrhythmic agents can result in or exaggerate the existing right
precordial ST elevation by further reducing sodium currents that are already affected by vari-
ants of SCN5A, the gene that encodes the α-subunit of cardiac sodium channels (hNav1.5).
Among various antiarrhythmic agents, those of class IC cause the most pronounced ST change
by strong blockage of the sodium channels, which may result in acquired forms of Brugada
Syndrome [5] or worsening of arrhythmias in patients with Brugada Syndrome [6, 7]. SCN5A
variants may cause unpredictable hNav1.5 response to antiarrythmic agents. For example, Itoh
et al. reported that the SCN5A variant p.N406S identified in Brugada Syndrome patients
enhanced use-dependent block of sodium currents with quinidine, a class IA antiarrythmic
agent, but the same variant abolished the block with pilsicainide [8]. On the other hand, we
demonstrated that a common SCN5A single nucleotide polymorphism can enhance use-depen-
dent block of hNav1.5 with quinidine, and with the class IC agent flecainide [9].
In this study, we report the case of a 66-year-old Japanese male who developed pilsicainide
induced Brugada-type ECG during pharmacotherapy of atrial arrhythmias. Genetic screening
identified a novel c.3982G>A variant in SCN5A, resulting in substitution of methionine for
valine at position 1328 (p.V1328M) located in the cytoplasmic loop between the segment 4 and
segment 5 of domain III of the protein. Biophysical modification of the hNav1.5 by p.V1328M
and its effects on sodium channel pharmacokinetics were studied using the patch-clampmethod.
Materials and Methods
Genetic screening and mutagenesis
Genetic analysis was performed according to the guidelines approved by the Institutional Eth-
ics Committee at Kyoto University. A written informed consent was obtained from the patient
and screened family members. Genomic DNA was isolated from leukocyte nuclei using the
QIAmp DNA Blood Midi Kit (QIAGEN GmbH, Hilden, Germany). Genetic screening for
SCN5A variants was done using denaturing high-performance liquid chromatography
(DHPLC: WAVE System Model 3500, Transgenomic, Omaha, NE). Direct DNA sequencing
was done with the ABI PRISM3100 DNA Sequencer (Applied Biosystems, Wellesley, MA).
Site-directed mutagenesis was performed with the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) using a vector containing theWT-SCN5A-Q1077 (NM_000335.4) as a
template. Mutant p.V1328M-SCN5A (hencefore V1328M) clones were verified by sequencing to
ensure the presence of the variant and the absence of other substitutions introduced by the DNA
polymerase.
Cell culture and transient expression of WT and V1328M
Transient transfection of HEK-293 cells (ATCC, CRL-1573) with WT and V1328M-SCN5A was
performed as described elsewhere [9]. Briefly, naïve HEK-293 cells were co-transfected with the
plasmid pcDNA3.1 containing either WT or V1328M-SCN5A along with pEGFP-C3 (Clontech,
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Mountain View, CA) encoding green fluorescent protein, using Lipofectamine 2000 transfection
reagent (Qiagen, Valencia, CA). The cells were incubated at 37°C for 2–3 days before use.
Patch-clamp experiments
Patch-clamp experiments were performed as described previously [9] using Axopatch 200A
amplifier and pClamp 9 software (Axon Instruments, Sunnyvale, CA). Whole-cell recordings
were carried out at 22°C. Series resistance was 2–5 MO. Currents were filtered at 10 kHz with a
built-in four-pole Bessel filter and digitized by a computer (Dell Optiplex GX280) at 20 kHz.
The pipette solution contained 10 NaF, 110 CsF, 20 CsCl, 10 EGTA, and 10 HEPES (in mM,
pH 7.35 with CsOH). Bath solution contained 145 NaCl, 4 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES,
and 10 glucose (in mM, pH 7.35 with NaOH). The estimated liquid junction potential was 8.1
mV and membrane potentials were corrected for it. Pilsicainide was kindly provided by Daiichi
Sankyo Co., LTD. (Tokyo, Japan). Whole-cell currents were analyzed using the Clampfit
(Axon Instruments, Sunnyvale, CA) and Igor softwares (Wavemetrics, Lake Oswego, OR).
Data were presented as mean ± SE. t-Test was used for statistical analysis.
Results
Clinical Observations
The patient was a 66-year-old Japanese male with history of type I atrial flutter and PAF (Fig
1A and 1B). His baseline ECG showed normal sinus rhythm and incomplete right bundle
branch block with mild ST elevation in lead V1 (Fig 1C). He had been treated with disopyra-
mide, a class IA antiarrhythmic agent, and verapamil. He had no personal or family history of
syncope or sudden cardiac death. His echocardiogram was normal. Three years into the above-
mentioned antiarrythmic treatment, atrial arrhythmias recurred necessitating DC cardiover-
sion. Post-cardioversion administration of pilsicainide caused marked coved type ST elevation
in lead V1 and saddle-back type ST elevation in lead V2 (Fig 2).
Electrophysiological study (EPS) was performed to evaluate for arrhythmia substrates. Dur-
ing EPS, type I atrial flutter was induced and cavotricuspid isthmus ablation was performed.
Furthermore, programmed stimulation induced VF (S1 Fig). The patient was discharged after
discontinuation of all antiarrhythmic agents.
Genetic Screening
Genetic screening revealed an aberrant band in the exon 23 of SCN5A (NM_198056) in the pro-
band, but not in his two siblings (Fig 3A and 3B). Direct sequencing identified a nucleotide
change, c.3982G>A, resulting in the substitution of methionine for valine at residue 1328 (p.
V1328M; Fig 3C and 3D). This variant could not be found in any database we searched, includ-
ing a local Japanese database (110 subjects, 220 alleles), the single nucleotide polymorphism data-
base (dbSNP, build 146) [10], the 1000 Genomes Browser database, phase 3 (2,500 subjects) [11],
the NHLBI Exome Sequencing Project (ESP) database (6,500 subjects) [12], and the Exome
Aggregation Consortium (ExAC) (60,312 subjects). These results suggest that SCN5A p.V1328M
is not a common variant. In addition, conservation analysis with the UCSC Genome Browser
showed that the V1328 residue is highly conserved in mammals and chicken, but substituted by
isoleucine in frog and zebrafish [13]. No other SCN5A variants were found in this patient.
Basal electrophysiological parameters of V1328M-SCN5A
Basal hNav1.5 characteristics of WT-SCN5A and V1328M-SCN5A were studied using the
whole-cell patch-clamp method. Fig 4A shows representative whole-cell current traces
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obtained from HEK-293 cells transfected with WT or V1328M-SCN5A. Current densities of
WT and the V1328M channels were nearly identical (WT: 163.9 ± 5.9 pA/pF, n = 10; V1328M:
158.9 ± 18.4 pA/pF, n = 10) (Fig 4B). Conductance normalized to peak conductance was plot-
ted against membrane potentials (Fig 4C). The data were fitted with the Boltzman’s equation.
Voltage-dependence of activation was not altered in the V1328Mmutant (Vh: WT, -42.6 ± 1.1
mV, n = 7; V1328M, -40.2 ± 0.8 mV, n = 7). However, voltage-dependence of steady-state inac-
tivation was shifted towards more positive potentials by 7 mV (Vh: WT, -100.2 ± 0.8 mV,
n = 7; V1328M, -93.1 ± 0.7 mV, n = 7, p<0.01) (Fig 4C and Table 1).
Recovery from fast inactivation was examined using a double-pulse protocol. Currents dur-
ing test pulse were normalized to currents during the pre-pulse state and plotted against inter-
vals between the two states (Fig 4D). The data were fitted with a double exponential function.
V1328M did not affect the time course of recovery from the inactivation state (n = 7). Table 1
summarizes gating kinetics parameters in the setting of no drugs.
Tonic block of WT and V1328M-SCN5A by pilsicainide
Tonic block of hNav1.5 by pilsicainide was studied using 20 ms depolarizing voltage steps to
-10 mV every 15 s from a holding potential of -120 mV. Fig 5A shows representative current
traces in the absence or presence of pilsicainide (50 μM). Fractional block was measured as the
ratio of the difference between peak currents in WT and V1328M to peak currents in WT and
Fig 1. ECG phenotypes. (A) Type I atrial flutter. (B) PAF.
doi:10.1371/journal.pone.0161872.g001
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was plotted as a function of pilsicainide concentration. Pilsicainide (50 μM) exerted similar
tonic block in WT and V1328M (% block with 50 μM pilsicainide: WT, 44.2 ± 0.01, n = 6;
V1328M, 38.6 ± 0.03, n = 6) (Fig 5B).
Use-dependent block of WT and V1328M-SCN5A by pilsicainide
Class I antiarrhythmic agents have been reported to show use-dependent block in voltage-
gated sodium channels [14]. Use-dependent block of WT and V1328M by pilsicainide was
assessed by application of a 2 Hz pulse train (150 ms at -10 mV) from a holding potential of
-120 mV. Fig 6A shows superimposed current traces in WT and V1328M cells in the absence
or presence of 10 μM pilsicainide. Currents at each pulse were normalized to the currents at
pulse #1 in the absence of the drug and plotted against the pulse number (Fig 6B). Fractional
block was estimated as the difference of peak currents at pulse #100 in the presence or absence
of the drug. V1328M was found to exhibit more use-dependent block than the WT (% block
with 10 μM pilsicainide: WT, 15.5 ± 0.02, n = 6; V1328M, 46.1 ± 0.01, n = 6, p =<0.001) (Fig
6C). Using the Hill equation, dose-response relationships were estimated yielding Ki values of
35.8 μM and 19.3 μM, and Hill coefficients of 1.4 and 1.1 for WT and V1328M, respectively.
Fig 2. ECG phenotypes on pilsicainide. Left panels show baseline ECGs and the right panels show the ECGs after intravenous injection of
pilsicainide (0.8 mg/kg).
doi:10.1371/journal.pone.0161872.g002
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Discussion
In this study, we report that the novel SCN5Amutation, p.V1328M, identified in a patient who
presented with drug-induced Brugada-type ECG, can enhance hNav1.5’s response to pilsicai-
nide. Our study also suggests that this SCN5Amutation which changes a residue in the cyto-
plasmic loop, can modify hNav1.5’s response to class IC antiarrhythmic agents that may bind
to the extracellular side of the channel.
Modification of hNav1.5 electrophysiological parameters by V1328M
Electrophysiological data obtained using the patch-clamp method demonstrated that V1328M
does not affect sodium current density. On the other hand, V1328M shifts the voltage-depen-
dence of steady-state inactivation toward positive by 7 mV without affecting activation kinetics,
with the end result of an increase in channel availability (i.e., gain-of-function). Interestingly,
several variants causing changes adjacent to residue 1328 have been identified in patients with
type 3 long-QT syndrome (LQT3) [15–19] and among those variants E1295K and A1330P
showed similar biophysical modifications of the Nav1.5 as V1328M (i.e., increase in window
currents) [15, 18]. However, our patient did not show LQTS phenotype (QTc = 413 ms) except
for being susceptible to VF (i.e., inducible VF). This might be due to the presence of unidenti-
fied compensatory mechanisms that can counteract the gain-of-function caused by V1328M.
Fig 3. Genetic analysis. (A) Family tree. The filled square indicates the proband. (B) Abnormal migration pattern identified with DHPLC in the
proband. (C) A nucleotide change (3982G>A) identified in the exon 23 of SCN5A (black arrow). (D) Schematic illustration of the SCN5A structure.
The red closed circle with the arrowhead indicates the location of p.V1328Mmutation.
doi:10.1371/journal.pone.0161872.g003
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Regardless, it is very unlikely that the gain-of-function in hNav1.5 caused by p.V1328M can
result in Brugada phenotype.
Does modification of hNav1.5 by V1328M account for the observed ECG
phenotype?
Approximately a hundred of SCN5Amutations were identified in patients with Brugada Syn-
drome. Electrophysiological studies using cell expression systems and animal models demon-
strated that the attenuated sodium channel function caused by these SCN5Amutations can
result in the loss of the action potential (AP) dome, thereby exaggerating the transmural repo-
larization gradient [20]. However, the extent of sodium channel modification required to cause
a loss in AP dome has not been fully elucidated. Although many SCN5Amutations reduce
Fig 4. Properties of control andmutant SCNA5 channels expressed in HEK-293 cells. (A) Superimposed whole-cell current traces recorded
in response to step changes in membrane voltage. 20 ms were applied in 5 mV increments from -100 to +75 mV from a holding potential (HP) of –
140 mV. (B) I-V relationships. (C) Voltage-dependence of peak conductance and steady-state inactivation. Conductance G(V) was calculated by
the equation: G(V) = I / (Vm—Erev), where I is the peak currents, Erev is the measured reversal potential, and Vm is the membrane potential.
Normalized peak conductance was plotted against membrane potentials. Steady-state inactivation was measured using a protocol consisting of a
500 ms pre-pulse ranging from -120 to -20 mV in 5 mV increments followed by a 20 ms testing pulse to -20 mV; HP = -140 mV. Normalized peak
currents at test pulses were plotted as a function of membrane potentials. Voltage-dependence of activation and inactivation were fitted with the
Boltzmann equation. (D) Recovery from fast inactivation estimated by a double pulse protocol (shown in the inset). The currents at the second
pulse were normalized to the currents at pre-pulse and plotted against intervals between the two pulses. The time course was fitted with a sum of
two exponentials.
doi:10.1371/journal.pone.0161872.g004
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sodium current densities by more than 80%, some of them decrease peak currents by only
~15% (e.g., L567Q and R1023H) [21, 22]. In our patient, V1328M significantly augmented
blockage of sodium currents caused by pilsicainide (by 20–30% more compared to WT) within
its therapeutic concentration range (10~25 μM; Fig 5C and 5D). Although V1328M might
enhance transmural AP dispersion by unidentified mechanisms, it is reasonable to conclude
that the pharmacological modification by V1328M, at least in part, accounts for the observed
ECG phenotypes.
Modification of hNav1.5 pharmacokinetics by V1328M
It has been reported that class I antiarrhythmic agents can block sodium channels by plugging
their pore from the intracellular side [23]. Studies using site-directed mutagenesis revealed that
the hydrophobic residues in the membrane spanning domain DIV-S6 (e.g., F1764 and Y1771)
might serve as common binding sites for these drugs through interaction with the drugs’
hydrophobic moieties [24, 25]. Several studies also indicated that class I antiarrhythmic agents,
passing through the channel pore or the plasma membrane, can bind to the residues in pore
lining domains [24–26].
Pilsicainide hydrochloride, a derivative of lidocaine, shares a similar hydrophobic structure
with drugs QX314 and QX222, the permanently charged lidocaine derivatives. Since most of
pilsicainide molecules are in a charged form at physiological pH (pKa = 10.5), it is possible to
speculate that pilsicainide may pass through the channel pore and interact with the common
binding sites [27].
Limitations
There are several limitations in our study: (1) Data were obtained using in vitro experiments
and a non-cardiomyocyte cell line expressing only the exogenous α-subunit of human cardiac
sodium channels; (2) Voltage-clamp pulse protocols used in the study were not physiological.
However, our study suggests that the subclinical p.V1328M mutation in SCN5Amight predis-
pose certain individuals to drug-induced Brugada Syndrome. We believe that this genotype-
Table 1. Parameters of WT and V1328M channels in the absence of drugs.
WT V1328M
Current density (pA/pF) (10) (10)
163.9 ± 5.9 158.9 ± 18.4
Activation (7) (7)
Vh (mV) -42.6 ± 1.1 -40.2 ± 0.8
k 8.9 ± 0.3 8.7 ± 0.4
Steady-state inactivation (7) (7)
Vh (mV) -100.2 ± 0.8 -93.1 ± 0.7٭
k 6.3 ± 0.6 6.7 ± 0.2
Recovery from fast-inactivation (7) (7)
τf (ms) 4.61 ± 0.49 4.51 ± 0.47
τs (ms) 53.4 ± 2.4 54.9 ± 2.1
Af 0.83 ± 0.02 0.93 ± 0.02
As 0.25 ± 0.02 0.18 ± 0.01
Vh, represents midpoint voltage of maximal activation/inactivation; k, slope factor; τf and τs the time constants
of fast and slow components of recovery; Af and As, the fraction of fast and slow components
*p <0.01; numbers in parenthesis, the number of patches.
doi:10.1371/journal.pone.0161872.t001
Drug Induced Brugada Syndrome
PLOSONE | DOI:10.1371/journal.pone.0161872 August 25, 2016 8 / 12
antiarrhythmic relationship could be incorporated in future treatment guidelines of Brugada
Syndrome.
Conclusion
A novel SCN5Amutation, p.V1328M, was identified in a patient who developed pilsicainide-
induced Brugada-type ST change. In vitro electrophysiological studies demonstrated that p.
V1328M can cause gain-of-function in the hNav1.5. p.V1328M was also found to enhance use-
dependent block of hNav1.5, which might account for the observed ST elevation. Thus, we con-
clude that subclinical SCN5A mutations such as p.V1328M could predispose certain individu-
als to acquired forms of Brugada Syndrome.
Fig 5. Tonic block of WT and V1328M by pilsicainide. (A) Representative traces in WT and V1328M in the absence or presence
of 50 μM pilsicainide. Currents were elicited every 15 seconds by 150 ms pulses to -20 mV from a holding potential of -120 mV. (B)
Dose-response relationship of the tonic block. The data were fitted with the Hill equation: y = 1/[1 + (x/Ki)n], where y represents the
fractional block; x is the concentration of quinidine; Ki is the half-maximal concentration of inhibition; and n is the Hill coefficient.
Numbers in parentheses are the number of patches.
doi:10.1371/journal.pone.0161872.g005
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Supporting Information
S1 Fig. VF was induced by programmed stimulation.
(TIF)
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